Fertility Preservation for Young Women with Breast Cancer: Review and Perspective

Shuxin Zheng, Limei Cai, Zhiming Miao, Yinlong YangClinical 2024 · DOI

Abstract

Breast cancer is a common malignancy that poses a significant danger to women. Recently, the risks of breast cancer have been increasing in younger populations, and treatments may affect the ability to conceive, requiring options for fertility preservation. The clinical management of breast cancer typically involves surgery, chemotherapy, and radiotherapy, all of which may present detrimental effects on fertility. Thus, it is crucial to consider fertility preservation when formulating treatment plans. This review analyzes the impact of breast cancer treatment modalities on fertility and evaluates strategies for preservation, including oocyte and embryo cryopreservation, controlled ovarian stimulation (COS), in vitro maturation (IVM), and ovarian tissue transplantation. Additionally, potential strategies such as 3D bioprinting, Traditional Chinese Medicine (TCM), and Artificial Intelligence (AI) assisted treatment are discussed. The integration of these technologies is expected to provide a new perspective for young breast cancer patients seeking to maintain their fertility.

Introduction

As advancements in oncology continue to improve survival rates for young women diagnosed with breast cancer, the focus of clinical care has expanded to include long-term quality-of-life issues. Among these, the preservation of reproductive potential is paramount. Many life-saving treatments, including chemotherapy, radiation, and endocrine therapy, are "gonadotoxic," meaning they can cause significant and often irreversible damage to the ovaries. This damage frequently leads to premature ovarian failure (POF) or infertility, presenting a profound psychological and physiological burden for survivors.

The Biological Impact of Treatment: The "Burnout" Mechanism

The primary challenge in preserving fertility lies in the biological mechanism of ovarian damage. Chemotherapy agents, particularly alkylating drugs like cyclophosphamide, do not merely kill oocytes directly. Instead, they often trigger a "burnout" effect. This phenomenon involves the massive, synchronized activation of dormant primordial follicles. Once activated, these follicles are rapidly depleted, exhausting the ovarian reserve in a very short period.

Furthermore, the timing of treatment presents a logistical hurdle. Traditional fertility preservation methods often require weeks of hormonal stimulation, which can delay urgent surgical interventions. Additionally, long-term endocrine therapies such as Tamoxifen, while effective against cancer, are teratogenic. Patients are often advised to wait 5–10 years before attempting conception, a timeframe during which natural fertility naturally declines.

Established Fertility Preservation Strategies

Current clinical practice relies on several validated techniques, each with specific indications and success rates. Evidence from major clinical trials, such as the SOFT and TEXT trials, has helped define the impact of these interventions on long-term reproductive health.

Oocyte and Embryo Cryopreservation

Oocyte cryopreservation remains the gold standard for single patients. Recent data indicates live birth and fertility rates between 34% and 42%. A significant advancement in this area is the implementation of "random-start" controlled ovarian stimulation (COS) protocols. Unlike traditional methods that require waiting for the start of a menstrual cycle, random-start COS allows for immediate egg harvesting, reducing the delay in cancer treatment to just 2–3 weeks.

Ovarian Tissue Transplantation (OTT)

OTT is particularly valuable for pre-adolescent patients or those who cannot delay chemotherapy. This method boasts a high tissue survival rate of up to 96% and live birth rates ranging from 40% to 43.3%. It involves the surgical removal and freezing of ovarian cortical tissue, which is later re-implanted after cancer treatment is complete.

In Vitro Maturation (IVM)

IVM involves harvesting immature eggs directly from the ovaries, bypassing the need for hormonal stimulation. This is an attractive option for patients with hormone-sensitive tumors or those requiring immediate treatment. Current studies show a fertilization rate of approximately 77.8% for IVM-derived oocytes.

GnRHa Co-administration

The use of Gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy acts as a "shield" for the ovaries. By suppressing the pituitary-gonadal axis, GnRHa reduces the risk of permanent amenorrhea, helping to maintain ovarian function post-treatment.

Emerging Frontiers in Reproductive Medicine

The future of fertility preservation is being shaped by three key technological pillars: 3D bioprinting, Artificial Intelligence, and the integration of Traditional Chinese Medicine.

3D Bioprinting and the Artificial Ovary

3D bioprinting is a frontier technology aimed at creating functional ovarian tissue. Researchers are utilizing gelatin-methacrylate bio-inks to construct scaffolds that mimic the natural ovarian microenvironment. These scaffolds can support the growth and maturation of follicles, potentially offering a way to restore endocrine function and fertility in the future.

Artificial Intelligence in IVF

AI is increasingly used to optimize laboratory outcomes in assisted reproduction. Machine learning algorithms can analyze vast datasets to predict the optimal timing for "trigger" injections and identify embryos with the highest implantation potential. By removing human subjectivity, AI enhances the precision and success rates of IVF procedures for cancer survivors.

Traditional Chinese Medicine (TCM)

TCM is being explored as a complementary strategy to mitigate the side effects of chemotherapy. Research suggests that certain TCM formulations can reduce oxidative stress in the ovaries and modulate molecular pathways to protect the follicular reserve. However, standardized, large-scale clinical validation is necessary before these practices can be fully integrated into standard oncological protocols.

Conclusion

The impact of breast cancer treatments on fertility is highly individualized, necessitating a personalized approach to preservation. While established methods like egg freezing and tissue transplantation offer reliable options, the integration of 3D bioprinting, AI, and TCM represents the next generation of care. By combining high-tech bioengineering with personalized medical management, clinicians can ensure that a cancer diagnosis is no longer a definitive barrier to a woman's reproductive goals.

Summary updated

Abstract

Objectives: Breast cancer is a common malignancy that poses a significant danger to women. Recently the risks of breast cancer have been increasing in younger populations, and treatments may affect the ability to conceive, requiring options for fertility preservation. The clinical management of breast cancer typically involves surgery, chemotherapy, and radiotherapy, all of which may present detrimental effects on fertility. Thus, it is crucial to consider fertility preservation when formulating treatment plans. Mechanism: A narrative review was conducted to analyze the available literature regarding the impact of breast cancer treatment modalities on fertility, as well as strategies for fertility preservation. Findings in Brief: Various breast cancer treatment modalities can result in varying degrees of damage to a patient’s ovaries, potentially compromising their ovarian function and subsequently affecting their fertility. This article reviews various fertility preservation methods, including oocyte and embryo cryopreservation, controlled ovarian stimulation (COS), in vitro maturation (IVM), cryopreservation, and ovarian tissue transplantation. Additionally, we discuss several potential strategies, such as 3D bioprinting, Traditional Chinese Medicine (TCM), and Artificial Intelligence (AI) assisted treatment. Conclusions: The impact of breast cancer treatment modalities and fertility preservation strategies exhibits individual variability, necessitating the clinical selection of treatment based on the specific circumstances of each patient. The integration of 3D bioprinting, TCM, and AI is expected to provide a new perspective for young breast cancer patients seeking to maintain their fertility.
BibTeX
@inproceedings{zheng2024fertility,
  author = {Shuxin Zheng and Limei Cai and Zhiming Miao and Yinlong Yang},
  title = {{Fertility Preservation for Young Women with Breast Cancer: Review and Perspective}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.31083/j.ceog5107150},
}
Figure